About Our Portfolio

NeurogesX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies based on known chemical entities. Our initial focus is on chronic peripheral neuropathic pain, which includes the conditions of postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN).

Our lead product candidate, Qutenza® (capsaicin) 8% patch, is a dermal high- concentration capsaicin patch which was approved by the in U.S. Food and Drug Administration in November 2009 and by the European Medicines Agency (EMEA) in May 2009. Qutenza is being investigated for other indications. .

In addition to Qutenza, we are developing NGX-1998, a non-patch liquid formulation of the same active ingredient (capsaicin) used in Qutenza. NGX-1998 is being designed to treat neuropathic pain conditions such as postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). NGX-1998 has completed three Phase 1 studies.

Our pre-clinical pipeline consists of two prodrug programs in which we modify the chemical make-up of well known, currently used drugs to improve their safety, efficacy and/or potential usefulness in the management of pain. We have conducted preclinical evaluations of one opioid prodrug compound (NGX-6052) and three acetaminophen prodrugs (NGX-5752, NGX-9674 and NGX-1576). Early results – particularly for the hepatoprotective NGX-1576 – are encouraging and we are currently seeking development partners for these programs.

The table below summarizes the status of our product and product candidates.

NEUROGESX INVESTIGATIONAL PRODUCT PIPELINE